...
首页> 外文期刊>Liver international : >Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis
【24h】

Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis

机译:肝硬化患者的循环和肝内大麻素及与大麻素相关的分子

获取原文
获取原文并翻译 | 示例

摘要

Background/Aims: Endocannabinoids include anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Endocannabinoid-related molecules like oleoyl-ethanolamine (OEA) and palmitoyl-ethanolamine (PEA) have also been identified. AEA contributes to the pathogenesis of cardiovascular alterations in experimental cirrhosis, but data on the endocannabinoid system in human cirrhosis are lacking. Thus, we aimed to assess whether circulating and hepatic endocannabinoids are upregulated in cirrhotic patients and whether their levels correlate with systemic haemodynamics and liver function. Methods: The endocannabinoid levels were measured in peripheral and hepatic veins and liver tissue by isotope-dilution liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. Systemic haemodynamics were assessed by the transthoracic electrical bioimpedance technique. Portal pressure was evaluated by hepatic venous pressure gradient. Results: Circulating AEA and, to a greater extent, PEA and OEA were significantly higher in cirrhotic patients than in controls. PEA and OEA were also increased in the cirrhotic liver tissue. AEA, OEA and PEA levels were significantly higher in peripheral than in the hepatic veins of cirrhotic patients, while the opposite occurred for 2-AG. Finally, circulating AEA, OEA and PEA correlated with parameters of liver function, such as serum bilirubin and international normalized ratio. No correlations were found with systemic haemodynamics. Conclusions: The endocannabinoid system is upregulated in human cirrhosis. Peripheral AEA is increased in patients with a high model of end-stage liver disease score and may reflect the extent of liver dysfunction. In contrast, the 2-AG levels, the other major endocannabinoid, are not affected by cirrhosis. The upregulation of the endocannabinoid-related molecules, OEA and PEA, is even greater than that of AEA, prompting pharmacological studies on these compounds.
机译:背景/目的:内源性大麻素包括七叶酰胺(AEA)和2-花生四烯酰甘油(2-AG)。内源性大麻素相关分子,如油酰乙醇胺(OEA)和棕榈酰乙醇胺(PEA)也已被鉴定。 AEA有助于实验性肝硬化中心血管改变的发病机理,但缺乏有关人类肝硬化中内源性大麻素系统的数据。因此,我们旨在评估肝硬化患者中循环和肝内大麻素是否上调,以及它们的水平是否与全身血液动力学和肝功能相关。方法:采用同位素稀释液相色谱-大气压化学电离-质谱法测定外周,肝静脉和肝组织中的大麻素水平。通过经胸电生物阻抗技术评估全身血流动力学。通过肝静脉压力梯度评估门静脉压力。结果:肝硬化患者的循环AEA以及更大程度的PEA和OEA显着高于对照组。肝硬化肝组织中的PEA和OEA也增加。肝硬化患者外周血的AEA,OEA和PEA水平明显高于肝静脉,而2-AG则相反。最后,循环中的AEA,OEA和PEA与肝功能参数有关,例如血清胆红素和国际标准化比率。没有发现与全身血流动力学的相关性。结论:内源性大麻素系统在肝硬化中被上调。晚期肝病评分较高的模型患者外周血AEA升高,可能反映了肝功能障碍的程度。相反,另一主要内源性大麻素2-AG的水平不受肝硬化的影响。内源性大麻素相关分子OEA和PEA的上调甚至大于AEA,从而促进了对这些化合物的药理研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号